Investigating Mechanisms Determining Cancer Cell Sensitivity to Carfilzomib and Novel Strategies to Overcome Resistance

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.13023/ETD.2017.004
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Relationship between the proteasomal system and autophagy.

  2017cited by this paper
• Proteasome inhibitors in cancer therapy

  2017cited by this paper
• Drugging the undruggables: exploring the ubiquitin system for drug development

  2016cited by this paper
• Spotlight on ixazomib: potential in the treatment of multiple myeloma

  2016cited by this paper
• Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism

  2016cited by this paper
• Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer

  2016cited by this paper
• Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study

  2016cited by this paper
• Identification of Doxorubicin as an Inhibitor of the IRE1α-XBP1 Axis of the Unfolded Protein Response

  2016cited by this paper
• The life cycle of the 26S proteasome: from birth, through regulation and function, and onto its death

  2016cited by this paper
• Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC-Dependent Cell Death in T-cell and Hodgkin Lymphoma.

  2016cited by this paper
• Ixazomib: First Global Approval

  2016cited by this paper
• Carfilzomib (Kyprolis): A Novel Proteasome Inhibitor for Relapsed And/or Refractory Multiple Myeloma.

  2016cited by this paper
• The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design

  2016cited by this paper
• Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy

  2016cited by this paper
• Predicting the response of multiple myeloma to the proteasome inhibitor Bortezomib by evaluation of the unfolded protein response

  2016cited by this paper
• Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.

  2016cited by this paper
• Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

  2016cited by this paper
• Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits

  2015cited by this paper
• Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.

  2015cited by this paper
• The immunoproteasome and viral infection: a complex regulator of inflammation

  2015cited by this paper
• Bortezomib-resistant mutant proteasomes: structural and biochemical evaluation with carfilzomib and ONX 0914.

  2015cited by this paper
• The Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediate Bortezomib Resistance in Multiple Myeloma*

  2015cited by this paper
• Proteasome inhibitors with pyrazole scaffolds from structure-based virtual screening.

  2015cited by this paper
• Role of the Ubiquitin-Proteasome Systems in the Biology and Virulence of Protozoan Parasites

  2015cited by this paper
• Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.

  2015cited by this paper
• Carfilzomib is an effective anticancer agent in anaplastic thyroid cancer.

  2015cited by this paper
• Harnessing Noxa demethylation to overcome Bortezomib resistance in mantle cell lymphoma

  2015cited by this paper
• The generation of antibody-secreting plasma cells

  2015cited by this paper
• Molecular mechanisms in multiple myeloma drug resistance

  2015cited by this paper
• Phase 1 Study of Carfilzomib for the Prevention of Relapse and Graft-Versus-Host Disease in Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

  2015cited by this paper
• TCR affinity for thymoproteasome-dependent positively selecting peptides conditions antigen responsiveness in CD8+ T cells

  2015cited by this paper
• The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells

  2015cited by this paper
• A proteomic analysis of p53-independent induction of apoptosis by bortezomib in 4T1 breast cancer cell line.

  2015cited by this paper
• Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma.

  2015cited by this paper
• Facile and Scalable Synthesis of Novel Spherical Au Nanocluster Assemblies@Polyacrylic Acid/Calcium Phosphate Nanoparticles for Dual-Modal Imaging-Guided Cancer Chemotherapy.

  2015cited by this paper
• KLF4-SQSTM1/p62-associated prosurvival autophagy contributes to carfilzomib resistance in multiple myeloma models

  2015cited by this paper
• Polymer Micelle Formulations of Proteasome Inhibitor Carfilzomib for Improved Metabolic Stability and Anticancer Efficacy in Human Multiple Myeloma and Lung Cancer Cell Lines

  2015cited by this paper
• Elucidating the Catalytic Subunit Composition of Distinct Proteasome Subtypes: A Crosslinking Approach Employing Bifunctional Activity‐Based Probes

  2015cited by this paper
• Mcl-1 downregulation sensitizes glioma to bortezomib-induced apoptosis.

  2015cited by this paper
• Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.

  2014cited by this paper
• Actively-targeted polyion complex micelles stabilized by cholesterol and disulfide cross-linking for systemic delivery of siRNA to solid tumors.

  2014cited by this paper
• The complexity of recognition of ubiquitinated substrates by the 26S proteasome.

  2014cited by this paper
• Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy

  2014cited by this paper
• Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models

  2014cited by this paper
• Proteasome inhibitors in acute leukemia

  2014cited by this paper
• The ubiquitin proteasome system - implications for cell cycle control and the targeted treatment of cancer.

  2014cited by this paper
• Liposomal carfilzomib nanoparticles effectively target multiple myeloma cells and demonstrate enhanced efficacy in vivo.

  2014cited by this paper
• Pre‐clinical efficacy of PU‐H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma

  2014cited by this paper
• A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis.

  2014cited by this paper
• Circumvention of Mcl-1-Dependent Drug Resistance by Simultaneous Chk1 and MEK1/2 Inhibition in Human Multiple Myeloma Cells

  2014cited by this paper
• Engineered nanomedicine for myeloma and bone microenvironment targeting

  2014cited by this paper
• Polymeric micelles as drug delivery vehicles

  2014cited by this paper
• The small heat shock protein B8 (HSPB8) confers resistance to bortezomib by promoting autophagic removal of misfolded proteins in multiple myeloma cells

  2014cited by this paper
• Proteasome inhibitors in acute leukemia

  2014cited by this paper
• Evolution of carfilzomib dose and schedule in patients with multiple myeloma: a historical overview.

  2014cited by this paper
• Utilization of Translational Bioinformatics to Identify Novel Biomarkers of Bortezomib Resistance in Multiple Myeloma

  2014cited by this paper
• Emerging therapies targeting the ubiquitin proteasome system in cancer.

  2014cited by this paper
• High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib

  2014cited by this paper
• Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors

  2014cited by this paper
• U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma

  2013cited by this paper
• Molecular architecture and assembly of the eukaryotic proteasome.

  2013cited by this paper
• Proteasome Maturation Protein (pomp) Is Associated With Proteasome Inhibitor Resistance In Myeloma, and Its Suppression Enhances The Activity Of Bortezomib and Carfilzomib

  2013cited by this paper
• A phase I/II study of carfilzomib 2–10-min infusion in patients with advanced solid tumors

  2013cited by this paper
• The proteasome under the microscope: the regulatory particle in focus.

  2013cited by this paper
• From epoxomicin to carfilzomib: chemistry, biology, and medical outcomes.

  2013cited by this paper
• Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma.

  2013cited by this paper
• New Strategies in the Treatment of Multiple Myeloma

  2013cited by this paper
• Identification of an ABCB1 (P‐glycoprotein)‐positive carfilzomib‐resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1

  2013cited by this paper
• Targeting the ubiquitin–proteasome system for cancer therapy

  2013cited by this paper
• Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors

  2013cited by this paper
• Exploring Polymeric Micelles for Improved Delivery of Anticancer Agents: Recent Developments in Preclinical Studies

  2013cited by this paper
• Inhibitors of the immunoproteasome: current status and future directions.

  2013cited by this paper
• The resistance mechanisms of proteasome inhibitor bortezomib

  2013cited by this paper
• From bortezomib to other inhibitors of the proteasome and beyond.

  2013cited by this paper
• Molecular Basis of Differential Sensitivity of Myeloma Cells to Clinically Relevant Bolus Treatment with Bortezomib

  2013cited by this paper
• A genome-wide siRNA screen identifies proteasome addiction as a vulnerability of basal-like triple-negative breast cancer cells.

  2013cited by this paper
• Clinical Pharmacokinetics, Metabolism, and Drug-Drug Interaction of Carfilzomib

  2013cited by this paper
• Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms

  2013cited by this paper
• Why proteasome inhibitors cannot ERADicate multiple myeloma.

  2013cited by this paper
• Multiple myeloma Leu167Ile (c.499C>A) mutation prevents XBP1 mRNA splicing

  2013cited by this paper
• BAK and NOXA Are Critical Determinants of Mitochondrial Apoptosis Induced by Bortezomib in Mesothelioma

  2013cited by this paper
• The proteasome: from basic mechanisms to emerging roles.

  2013cited by this paper
• Preclinical evaluation of Genexol-PM, a nanoparticle formulation of paclitaxel, as a novel radiosensitizer for the treatment of non-small cell lung cancer.

  2013cited by this paper
• Endoplasmic Reticulum Stress and the Unfolded Protein Response: Targeting the Achilles Heel of Multiple Myeloma

  2013cited by this paper
• A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.

  2012cited by this paper
• Carfilzomib

  2012cited by this paper
• Inactivating PSMB5 Mutations and P-Glycoprotein (Multidrug Resistance-Associated Protein/ATP-Binding Cassette B1) Mediate Resistance to Proteasome Inhibitors: Ex Vivo Efficacy of (Immuno)Proteasome Inhibitors in Mononuclear Blood Cells from Patients with Rheumatoid Arthritis

  2012cited by this paper
• Proteasome inhibitors in multiple myeloma: 10 years later.

  2012cited by this paper
• Emerging roles of immunoproteasomes beyond MHC class I antigen processing

  2012cited by this paper
• Development of peptide-based reversing agents for p-glycoprotein-mediated resistance to carfilzomib.

  2012cited by this paper
• An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma.

  2012cited by this paper
• Bortezomib induces G2-M arrest in human colon cancer cells through ROS-inducible phosphorylation of ATM-CHK1.

  2012cited by this paper
• A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma

  2012cited by this paper
• Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.

  2012cited by this paper
• Pivotal Advance: Protein synthesis modulates responsiveness of differentiating and malignant plasma cells to proteasome inhibitors

  2012cited by this paper
• Activation of ATF4 mediates unwanted Mcl-1 accumulation by proteasome inhibition.

  2012cited by this paper
• Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy.

  2012cited by this paper
• Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1

  2012cited by this paper
• Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma

  2012cited by this paper
• Development of proteasome inhibitors as research tools and cancer drugs

  2012cited by this paper

• Effects of carfilzomib alone and in combination with cisplatin on the cell death in cisplatin-sensitive and cisplatin-resistant ovarian carcinoma cell lines.

  2019cites this paper